Literature DB >> 29782346

Claudins and nephrolithiasis.

Allein Plain1, R Todd Alexander1,2,3.   

Abstract

PURPOSE OF REVIEW: The greatest risk factor for kidney stone formation is increased urinary calcium excretion. Most filtered calcium is reabsorbed from the proximal tubule and the thick ascending limb (TAL) of Henle's loop via a paracellular pathway. Claudins are tight junction proteins that confer the permeability properties of an epithelium. We review the contribution of renal claudins to nephron calcium permeability and how perturbations in these pathways cause alterations in tubular calcium transport, hypercalciuria, nephrocalcinosis, or nephrolithiasis. RECENT
FINDINGS: Claudin-16 and Claudin-19 form a complex with claudin-3 enabling divalent cation permeability in the TAL. Claudin-14 interacts with claudin-16 to attenuate calcium permeability through this pore. Intronic mutations in claudin-14 increase expression causing hypercalciuria and kidney stones. A different type of TAL tight junction pore is composed of claudin-10b, which does not preferentially permeate calcium. Deletion of claudin-10b results in increased expression of the claudin-16/claudin-19 complex expressed in the medullary TAL and nephrocalcinosis.
SUMMARY: Alterations to claudins expressed in the TAL tight junction greatly affects calcium homeostasis as highlighted by point mutations in claudin-16 or claudin-19 causing FHHNC or gain of function mutations in claudin-14 causing kidney stones.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29782346     DOI: 10.1097/MNH.0000000000000426

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  9 in total

1.  Inching toward a Greater Understanding of Genetic Hypercalciuria: The Role of Claudins.

Authors:  Ronak Jagdeep Shah; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-19       Impact factor: 8.237

Review 2.  Nephrolithiasis secondary to inherited defects in the thick ascending loop of henle and connecting tubules.

Authors:  Nicolas Faller; Nasser A Dhayat; Daniel G Fuster
Journal:  Urolithiasis       Date:  2018-11-20       Impact factor: 3.436

3.  Mutations in CLDN2 Are Not a Common Cause of Pediatric Idiopathic Hypercalciuria in Canada.

Authors:  Emma H Ulrich; Elizabeth Harvey; Catherine J Morgan; Maury Pinsk; Robin Erickson; Lisa A Robinson; R Todd Alexander
Journal:  Can J Kidney Health Dis       Date:  2022-05-19

4.  Use of whole-exome sequencing to identify a novel ADCY10 mutation in a patient with nephrolithiasis.

Authors:  Chenyu Wang; Ran Du; Jieyuan Jin; Yi Dong; Jishi Liu; Liangling Fan; Rong Xiang
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

5.  Claudin-2 and claudin-12 form independent, complementary pores required to maintain calcium homeostasis.

Authors:  Megan R Beggs; Kennedi Young; Wanling Pan; Debbie D O'Neill; Matthew Saurette; Allein Plain; Juraj Rievaj; Michael R Doschak; Emmanuelle Cordat; Henrik Dimke; R Todd Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-30       Impact factor: 11.205

6.  Claudins in kidney health and disease.

Authors:  Chor Ho Jo; Sua Kim; Gheun-Ho Kim
Journal:  Kidney Res Clin Pract       Date:  2022-03-15

7.  Childhood nephrolithiasis and nephrocalcinosis caused by metabolic diseases and renal tubulopathy: A retrospective study from 2 tertiary centers.

Authors:  Jameela A Kari; Mohamed A Shalaby; Faiza A Qari; Amr S Albanna; Khalid A Alhasan
Journal:  Saudi Med J       Date:  2022-01       Impact factor: 1.422

Review 8.  Molecular mechanisms altering tubular calcium reabsorption.

Authors:  Mallory L Downie; R Todd Alexander
Journal:  Pediatr Nephrol       Date:  2021-04-01       Impact factor: 3.714

9.  Temporal Effects of Quercetin on Tight Junction Barrier Properties and Claudin Expression and Localization in MDCK II Cells.

Authors:  Enrique Gamero-Estevez; Sero Andonian; Bertrand Jean-Claude; Indra Gupta; Aimee K Ryan
Journal:  Int J Mol Sci       Date:  2019-10-02       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.